Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio ...

Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, ...

(Avedro) of $4.8 million in Q3 2026 and $5.5 million in Q3 2025. • Mobius acquisition-related amortization expense of ...

Current CEO, Tony Zook, to then transition to Executive Chairman Expanded Medicare-coverage for RaDaR ST to include ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global ...

Idorsia Ltd (SIX: IDIA) is a commercial-stage biopharmaceutical company with two products, each with blockbuster potential, ...

Eastman Kodak Company today announced the expansion of its KODAK PHARMACEUTICALS portfolio with the addition of KODAK® Normal ...

Treprostinil-Iloprost SMI combines two potent prostacyclin analogues, treprostinil and iloprost. The therapy is intended to ...

Cairn Surgical, Inc., an innovative medical technology company striving to make breast cancer surgery more precise, today ...

First-in-human study evaluates Strand’s ability to unlock the potential of systemic mRNA-encoded medicines with an IL-12 ...

(NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today ...

(Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, ...